BioCardia anticipates Japan PMDA review and FDA meeting request on CardiAMP in Q4 2025 while advancing clinical programs
Source: SeekingAlpha
2025-11-13 00:12:19 ET
More on BioCardia
- BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
- BioCardia GAAP EPS of -$0.24 misses by $0.01
- BioCardia announces pricing of up to $12M public offering
- Seeking Alpha’s Quant Rating on BioCardia
- Historical earnings data for BioCardia
Read the full article on Seeking Alpha
For further details see:
BioCardia anticipates Japan PMDA review and FDA meeting request on CardiAMP in Q4 2025 while advancing clinical programs
BioCardia Inc.
NASDAQ: BCDA
BCDA Trading
-1.27% G/L:
$1.30 Last:
32,329 Volume:
$1.2475 Open:
BCDA Latest News
March 03, 2026 08:00:00 am
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
February 10, 2026 10:31:15 am
BioCardia Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter
BCDA Stock Data
$13,478,172
8,766,118
2.53%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
Sunnyvale
